Literature DB >> 17160002

Advances in combating fungal diseases: vaccines on the threshold.

Jim E Cutler1, George S Deepe, Bruce S Klein.   

Abstract

The dramatic increase in fungal diseases in recent years can be attributed to the increased aggressiveness of medical therapy and other human activities. Immunosuppressed patients are at risk of contracting fungal diseases in healthcare settings and from natural environments. Increased prescribing of antifungals has led to the emergence of resistant fungi, resulting in treatment challenges. These concerns, together with the elucidation of the mechanisms of protective immunity against fungal diseases, have renewed interest in the development of vaccines against the mycoses. Most research has used murine models of human disease and, as we review in this article, the knowledge gained from these studies has advanced to the point where the development of vaccines targeting human fungal pathogens is now a realistic and achievable goal.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17160002      PMCID: PMC2214303          DOI: 10.1038/nrmicro1537

Source DB:  PubMed          Journal:  Nat Rev Microbiol        ISSN: 1740-1526            Impact factor:   60.633


  163 in total

1.  Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis.

Authors:  Y Han; M A Ulrich; J E Cutler
Journal:  J Infect Dis       Date:  1999-06       Impact factor: 5.226

2.  Fab fragments from a monoclonal antibody against a germ tube mannoprotein block the yeast-to-mycelium transition in Candida albicans.

Authors:  M Casanova; J P Martínez; W L Chaffin
Journal:  Infect Immun       Date:  1990-11       Impact factor: 3.441

3.  Phagocytosis of Histoplasma capsulatum yeasts and microconidia by human cultured macrophages and alveolar macrophages. Cellular cytoskeleton requirement for attachment and ingestion.

Authors:  S L Newman; C Bucher; J Rhodes; W E Bullock
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

4.  Th1 and Th2 cytokine secretion patterns in murine candidiasis: association of Th1 responses with acquired resistance.

Authors:  L Romani; S Mocci; C Bietta; L Lanfaloni; P Puccetti; F Bistoni
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

5.  Complex requirements for nascent and memory immunity in pulmonary histoplasmosis.

Authors:  R Allendörfer; G D Brunner; G S Deepe
Journal:  J Immunol       Date:  1999-06-15       Impact factor: 5.422

6.  Resistance to Coccidioides immitis in mice after immunization with recombinant protein or a DNA vaccine of a proline-rich antigen.

Authors:  R O Abuodeh; L F Shubitz; E Siegel; S Snyder; T Peng; K I Orsborn; E Brummer; D A Stevens; J N Galgiani
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

7.  Direct gene transfer into mouse muscle in vivo.

Authors:  J A Wolff; R W Malone; P Williams; W Chong; G Acsadi; A Jani; P L Felgner
Journal:  Science       Date:  1990-03-23       Impact factor: 47.728

8.  Autoantibody to heat-shock protein 90 can mediate protection against systemic candidosis.

Authors:  R C Matthews; J P Burnie; D Howat; T Rowland; F Walton
Journal:  Immunology       Date:  1991-09       Impact factor: 7.397

9.  Strain variation in antiphagocytic activity of capsular polysaccharides from Cryptococcus neoformans serotype A.

Authors:  J M Small; T G Mitchell
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

10.  Immunity to a pulmonary Cryptococcus neoformans infection requires both CD4+ and CD8+ T cells.

Authors:  G B Huffnagle; J L Yates; M F Lipscomb
Journal:  J Exp Med       Date:  1991-04-01       Impact factor: 14.307

View more
  77 in total

1.  Extracellular proteome of Aspergillus terreus grown on different carbon sources.

Authors:  Mee-Jung Han; Nag-Jong Kim; Sang Yup Lee; Ho Nam Chang
Journal:  Curr Genet       Date:  2010-06-08       Impact factor: 3.886

Review 2.  An insight into the antifungal pipeline: selected new molecules and beyond.

Authors:  Luis Ostrosky-Zeichner; Arturo Casadevall; John N Galgiani; Frank C Odds; John H Rex
Journal:  Nat Rev Drug Discov       Date:  2010-08-20       Impact factor: 84.694

3.  Vaccine and monoclonal antibody that enhance mouse resistance to candidiasis.

Authors:  Hong Xin; Jim E Cutler
Journal:  Clin Vaccine Immunol       Date:  2011-08-10

4.  Design of a mimotope-peptide based double epitope vaccine against disseminated candidiasis.

Authors:  Hong Xin; Pati Glee; Abby Adams; Farhan Mohiuddin; Karen Eberle
Journal:  Vaccine       Date:  2019-03-28       Impact factor: 3.641

Review 5.  Anticandidal immunity and vaginitis: novel opportunities for immune intervention.

Authors:  Antonio Cassone; Flavia De Bernardis; Giorgio Santoni
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

6.  Interleukin 1 enhances vaccine-induced antifungal T-helper 17 cells and resistance against Blastomyces dermatitidis infection.

Authors:  Marcel Wüthrich; Vanessa LeBert; Kevin Galles; Jane Hu-Li; Shlomo Z Ben-Sasson; William E Paul; Bruce S Klein
Journal:  J Infect Dis       Date:  2013-06-20       Impact factor: 5.226

7.  Vaccines to prevent systemic mycoses: holy grails meet translational realities.

Authors:  John N Galgiani
Journal:  J Infect Dis       Date:  2008-04-01       Impact factor: 5.226

8.  Evaluation of two homologous proline-rich proteins of Coccidioides posadasii as candidate vaccines against coccidioidomycosis.

Authors:  Roger A Herr; Chiung-Yu Hung; Garry T Cole
Journal:  Infect Immun       Date:  2007-09-17       Impact factor: 3.441

9.  Progress Toward a Human Vaccine Against Coccidioidomycosis.

Authors:  Garry T Cole; Brady J Hurtgen; Chiung-Yu Hung
Journal:  Curr Fungal Infect Rep       Date:  2012-12-01

Review 10.  Histoplasma capsulatum at the host-pathogen interface.

Authors:  Joshua D Nosanchuk; Attila Gacser
Journal:  Microbes Infect       Date:  2008-07-10       Impact factor: 2.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.